[Click eStock] "Hans Biomed, Leading Stock with Increasing Lifting Procedures"

Hanyang Securities analyzed on the 20th that Hans Biomed is expected to experience explosive growth as lifting procedures increase.

Hans Biomed is a company that develops and sells various medical-related products. Its main product lines include human tissue grafts, medical devices (lifting threads), and silicone (breast implants). As of last year, human tissue grafts accounted for 32.4 billion KRW (43.5%), medical devices 34.2 billion KRW (46.0%), silicone 1.9 billion KRW (2.5%), and others 5.9 billion KRW (7.9%).

Byungyong Oh, a researcher at Hanyang Securities, stated, “Among these, we focus on the lifting thread product ‘Mint lift,’ which accounted for most of last year’s medical device sales,” and added, “Thanks to the high growth of lifting threads, Hans Biomed has overcome two years of operating losses and successfully achieved a turnaround.”

Researcher Oh explained, “As lifting procedures are gradually becoming known and popularized domestically and internationally, the number of procedures has significantly increased in recent years, and the company holding the dominant domestic market share with the product ‘Mint lift’ is the biggest beneficiary,” adding, “What is more special is that 51% of the 32.6 billion KRW in ‘Mint lift’ sales comes from the U.S. market.”

‘Mint lift’ is the only Korean product that has received FDA approval and has currently become the overwhelming number one product in the U.S. Although lifting procedures are well known in Korea, they are still in the early stages in the U.S.

Researcher Oh analyzed, “In the past, when Korean medical devices entered large overseas markets, the stock prices of those companies received significant premiums,” and said, “Hans Biomed can be seen as a company at the beginning stage of entering the U.S. market with lifting threads.”

He also stated, “In addition to lifting threads, the company has established a 50-50 joint venture (Revos Biotechnology) with China’s Weigo Group (market cap approximately 10 trillion KRW) to prepare for sales of human tissue grafts in the Chinese market,” and added, “The Chinese factory will be completed in the first half of this year, and sales in China will begin in 2025.”

He continued, “Another domestic company advancing into the Chinese skin graft market is L&C Bio (market cap 526.3 billion KRW),” and analyzed, “Hans Biomed also has momentum for entering the Chinese market similar to L&C Bio, but its market capitalization is only about 128.6 billion KRW.”